|Abstract:||(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, its preparation and pharmaceutical compositions containing the same. It can be prepared either by reacting (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid successively with an alkyl haloformate and with ammonia, or, by cyclizing an (S)-2-amino-butanamide of the formula X--CH.sub.2 CH.sub.2 --Y--NHCH(C.sub.2 H.sub.5)CONH.sub.2 wherein Y is a --CH.sub.2 -- radical when X represents a ZOOC-- radical and Y is a --CO-- radical when X represents a HalCH.sub.2 -- radical, Z being a C.sub.1 -C.sub.4 alkyl radical and Hal a halogen atom. This laevorotatory enantiomer has been found to have significantly higher protective activity against hypoxia and ischemia than the corresponding racemate.|
|Inventor(s):||Gobert; Jean (Brussels, BE), Geerts; Jean-Pierre (Leglise, BE), Bodson; Guy (Bellefontaine, BE)|
|Assignee:||U C B Societe Anonyme (Brussels, BE)|
1. (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide substantially free of (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide.
2. (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide substantially free of (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, prepared by the process which comprises reacting (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid successively with (1) an alkyl haloformate of the formula HalCOOZ in which Hal represents a halogen atom and Z represents an alkyl radical having 1 to 4 carbon atoms, and with (2) ammonia.